---
title: "執行董事陳文遠減持新意網集團 30 萬股 每股作價約 6.31 港元"
description: "香港聯交所最新資料顯示，5 月 12 日，執行董事陳文遠減持新意網集團 30 萬股，每股作價 6.3123 港元，總金額約為 189.37 萬港元。增持後最新持股數目為 341.2 萬股，最新持股比例為 0.14%。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/240521300.md"
published_at: "2025-05-16T07:40:02.000Z"
---

# 執行董事陳文遠減持新意網集團 30 萬股 每股作價約 6.31 港元

> 香港聯交所最新資料顯示，5 月 12 日，執行董事陳文遠減持新意網集團 30 萬股，每股作價 6.3123 港元，總金額約為 189.37 萬港元。增持後最新持股數目為 341.2 萬股，最新持股比例為 0.14%。

智通財經 APP 獲悉，香港聯交所最新資料顯示，5 月 12 日，執行董事陳文遠減持新意網集團 (01686) 30 萬股，每股作價 6.3123 港元，總金額約為 189.37 萬港元。增持後最新持股數目為 341.2 萬股，最新持股比例為 0.14%。

### Related Stocks

- [01686.HK - 新意網集團](https://longbridge.com/zh-HK/quote/01686.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Standard Chartered PLC (OTCMKTS:SCBFF) Sees Significant Growth in Short Interest | Standard Chartered PLC (OTCMKTS:SCBFF) experienced a significant increase in short interest, rising 21.1% to 210,583 sha | [Link](https://longbridge.com/zh-HK/news/276119010.md) |
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/zh-HK/news/276051793.md) |
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/zh-HK/news/276035104.md) |
| UBS Remains a Buy on Netease Inc (9999) | UBS analyst maintained a Buy rating on Netease Inc yesterday and set a price target of HK$280.80.Valentine's Day Sale -  | [Link](https://longbridge.com/zh-HK/news/275830949.md) |
| Italy says it stands ready to train police in Gaza | Italy's Foreign Minister Antonio Tajani announced the country's readiness to train police forces in Gaza and the Palesti | [Link](https://longbridge.com/zh-HK/news/276056959.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。